	US 12,275,986 B2
	Biomarkers associated with checkpoint immune therapy and methods of using same
Chuan-Yuan Li, Durham, NC (US); and Dong Pan, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Filed by Duke University, Durham, NC (US)
Filed on Jan. 6, 2021, as Appl. No. 17/142,844.
Claims priority of provisional application 62/957,370, filed on Jan. 6, 2020.
Prior Publication US 2021/0207198 A1, Jul. 8, 2021
Int. Cl. C12Q 1/6827 (2018.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC C12Q 1/6827 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12Q 2535/101 (2013.01)]

13 Claims

1. A method for treating cancer in a subject comprising:

(a) detecting the presence or absence of a mutation in each of a plurality of genes associated with responsiveness to immune checkpoint blockade (ICB) therapy, in a biological sample from a subject having non-small cell lung cancer (NSCLC),

wherein the plurality of genes associated with responsiveness to ICB therapy consists of the genes: ABLI, ASXLI, ATM, BCOR, BRCA2, BRIP1, CARD11, CD79B, CDC73, CIC, EPHA3, EPHAS, EPHA, EPHB1, ERBB4, ERCC4, FGFR4, FLT3, FOXL2, HGF, INHBA, JAK3, MAX, MDC1, MED12, MET, MGA, MRE11, MSH2 NF2, NFKBIA, NOTCH1, NOTCH2, NTRK3, NUF, PARP], PAX5, PGR, PIK3C2G, PIK3C3, PIK3CG, PIM1, POLE, PPMID, PPP2RIA, PTPRD, RET, STAT3, TENT, TET1, TSC2, and ZFHX3; and

(b) administering an ICB therapy to the subject having cancer when the subject has mutations in two or more of the plurality of genes associated with responsiveness to ICB therapy.